

Symposia of the 125th Annual Meeting of the Pharmaceutical Society of Japan

S32 Recent progress in molecular target therapy on cancer

S32-1 Molecular target study of cancer on the basis of the interaction between small molecular compounds and their binding proteins

Hiroyuki Osada (Discovery Research Institute, RIKEN)

S32-2 Induction of anoikis sensitivity by MEK inhibitors

Hidesuke Fukazawa (Natl. Inst. Infect. Diseases)

S32-3 IAP as a molecular target for cancer therapy

Mikihiko Naito (Inst. Mol. Cell. Biosci., Univ. Tokyo)

S32-4 Progress of antibody-based cancer therapy: High-ADCC antibody

Kenya Shitara (Tokyo Research Laboratories, Kyowa Hakko Kogyo Co.LTD.)

S32-5 SNPs in the drug transporter genes in relation to the sensitivity to anticancer drugs

Yoshikazu Sugimoto (Kyoritsu University of Pharmacy)

S32-6 Molecular targeted therapeutics against cancer

Saburo Sone (Inst. Health Biosciences, Univ Tokushima Graduate School)